{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T03:19:56Z","timestamp":1764645596183},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Although some kinds of endoluminal surgery for patients with proton pump inhibitor (PPI)-refractory gastroesophageal reflux disease (GERD) have been reported, there are few reports on their long-term outcomes. In 2014, we reported the effectiveness of endoscopic surgery for PPI-refractory GERD, which we invented and named endoscopic submucosal dissection for GERD (ESD-G) in 2008. Thereafter, we accumulated more cases and monitored the patients\u2019 condition postoperatively and describe the outcomes herein.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods<\/jats:title><jats:p>This single-center, single-arm trial was conducted at the Osaka Medical and Pharmaceutical University Hospital. We compared outcomes between before and 3\u20136\u00a0months after ESD-G. Additionally, we investigated the outcomes of patients 5 or more years after ESD-G.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We performed 42 ESD-G procedures in 35 patients between 2008 and 2020. In seven patients, ESD-G was performed twice for various reasons. The frequency scale for the symptoms of GERD score was significantly improved 3\u20136\u00a0months after ESD-G (22\u2009\u2192\u200910,<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001); the Los Angeles classification for reflux esophagitis was clearly improved after ESD-G (<jats:italic>p<\/jats:italic>\u2009=\u20090.0423). The number of reflux episodes was not decreased by ESD-G. There was a significant difference in the potency unit of gastric acid secretion suppressants for controlling GERD-related symptoms between baseline and 3\u20136\u00a0months after ESD-G (<jats:italic>p<\/jats:italic>\u2009=\u20090.0009). In patients without a history of distal gastrectomy who underwent ESD-G, the potency unit of gastric acid secretion suppressants significantly decreased 5 or more years after ESD-G (<jats:italic>p<\/jats:italic>\u2009=\u20090.0121).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>ESD-G may be effective in patients with refractory GERD-related symptoms without a history of distal gastrectomy.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12876-021-02022-x","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T17:07:44Z","timestamp":1637255264000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Outcomes of endoscopic submucosal dissection for gastroesophageal reflux disease (ESD-G) for medication-refractory gastroesophageal reflux disease: 35 cases underwent ESD-G including 15 cases followed more than 5\u00a0years"],"prefix":"10.1186","volume":"21","author":[{"given":"Kazuhiro","family":"Ota","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihisa","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Iwatsubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shimpei","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Tokioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhide","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,18]]},"reference":[{"key":"2022_CR1","first-page":"6","volume":"8","author":"MB Fennerty","year":"2006","unstructured":"Fennerty MB, Johnson DA. Heartburn severity does not predict disease severity in patients with erosive esophagitis. Med Gen Med. 2006;8:6.","journal-title":"Med Gen Med"},{"key":"2022_CR2","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1053\/j.gastro.2003.12.001","volume":"126","author":"DA Johnson","year":"2004","unstructured":"Johnson DA, Fennerty MB. Heartburn severity underestimates erosive esophagitis severity in elderly patients with gastroesophageal reflux disease. Gastroenterology. 2004;126:660\u20134.","journal-title":"Gastroenterology"},{"key":"2022_CR3","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1023\/B:DDAS.0000007857.15694.15","volume":"48","author":"K Okamoto","year":"2003","unstructured":"Okamoto K, Iwakiri R, Mori M, et al. Clinical symptoms in endoscopic reflux esophagitis: evaluation in 8031 adult subjects. Dig Dis Sci. 2003;48:2237\u201341.","journal-title":"Dig Dis Sci"},{"key":"2022_CR4","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1007\/s00535-008-2228-z","volume":"43","author":"K Tsuboi","year":"2008","unstructured":"Tsuboi K, Omura N, Yano F, et al. Relationship of the frequency scale for symptoms of gastroesophageal reflux disease with endoscopic findings of cardiac sphincter morphology. J Gastroenterol. 2008;43:798\u2013802.","journal-title":"J Gastroenterol"},{"key":"2022_CR5","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1053\/gast.1997.v112.pm9178669","volume":"112","author":"N Chiba","year":"1997","unstructured":"Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112:1798\u2013810.","journal-title":"Gastroenterology"},{"key":"2022_CR6","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1111\/jgh.14664","volume":"34","author":"H Miyazaki","year":"2019","unstructured":"Miyazaki H, Igarashi A, Takeuchi T, et al. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: a systematic review. J Gastroenterol Hepatol. 2019;34:1316\u201328.","journal-title":"J Gastroenterol Hepatol"},{"key":"2022_CR7","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s00535-019-01609-2","volume":"54","author":"Y Yokoya","year":"2019","unstructured":"Yokoya Y, Igarashi A, Uda A, et al. Cost-utility analysis of a \u201cvonoprazan-first\u201d strategy versus \u201cesomeprazole- or rabeprazole-first\u201d strategy in GERD. J Gastroenterol. 2019;54:1083\u201395.","journal-title":"J Gastroenterol"},{"key":"2022_CR8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1365-2036.2010.04508.x","volume":"33","author":"Y Kinoshita","year":"2011","unstructured":"Kinoshita Y, Ashida K, Hongo M, Japan Rabeprazole Study Group for NERD. Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2011;33:213\u201324.","journal-title":"Aliment Pharmacol Ther"},{"key":"2022_CR9","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1111\/j.1572-0241.2002.05769.x","volume":"97","author":"P Miner Jr","year":"2002","unstructured":"Miner P Jr, Orr W, Filippone J, et al. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol. 2002;97:1332\u20139.","journal-title":"Am J Gastroenterol"},{"key":"2022_CR10","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2036.2010.04517.x","volume":"33","author":"H Miwa","year":"2011","unstructured":"Miwa H, Inoue K, Ashida K, et al. Randomised clinical trial: efficacy of the addition of a prokinetic, mosapride citrate, to omeprazole in the treatment of patients with non-erosive reflux disease\u2014a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2011;33:323\u201332.","journal-title":"Aliment Pharmacol Ther"},{"key":"2022_CR11","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/jgh.13970","volume":"33","author":"T Takeuchi","year":"2018","unstructured":"Takeuchi T, Takahashi Y, Kawaguchi S, et al. Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: ACOTIAMIDE plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor. J Gastroenterol Hepatol. 2018;33:623\u201330.","journal-title":"J Gastroenterol Hepatol"},{"key":"2022_CR12","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1007\/s00535-013-0896-9","volume":"49","author":"K Tominaga","year":"2014","unstructured":"Tominaga K, Kato M, Takeda H, et al. A randomized, placebo-controlled, double-blind clinical trial of rikkunshito for patients with non-erosive reflux disease refractory to proton-pump inhibitor: the G-PRIDE study. J Gastroenterol. 2014;49:1392\u2013405.","journal-title":"J Gastroenterol"},{"key":"2022_CR13","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1007\/s00535-019-01588-4","volume":"54","author":"T Takeuchi","year":"2019","unstructured":"Takeuchi T, Hongo H, Kimura T, et al. Efficacy and safety of hangeshashinto for treatment of GERD refractory to proton pump inhibitors: usual dose proton pump inhibitors plus hangeshashinto versus double-dose proton pump inhibitors: randomized, multicenter open label exploratory study. J Gastroenterol. 2019;54:972\u201383.","journal-title":"J Gastroenterol"},{"key":"2022_CR14","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1007\/s00464-011-1585-5","volume":"25","author":"M Anvari","year":"2011","unstructured":"Anvari M, Allen C, Marshall J, et al. A randomized controlled trial of laparoscopic Nissen fundoplication versus proton pump inhibitors for the treatment of patients with chronic gastroesophageal reflux disease (GERD): 3-year outcomes. Surg Endosc. 2011;25:2547\u201354.","journal-title":"Surg Endosc"},{"key":"2022_CR15","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1001\/jama.285.18.2331","volume":"285","author":"SJ Spechler","year":"2001","unstructured":"Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA. 2001;285:2331\u20138.","journal-title":"JAMA"},{"key":"2022_CR16","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00535-009-0064-4","volume":"44","author":"S Ozawa","year":"2009","unstructured":"Ozawa S, Kumai K, Higuchi K, et al. Short-term and long-term outcome of endoluminal gastroplication for the treatment of GERD: the first multicenter trial in Japan. J Gastroenterol. 2009;44:675\u201384.","journal-title":"J Gastroenterol"},{"key":"2022_CR17","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s00535-007-2005-4","volume":"2","author":"K Higuchi","year":"2007","unstructured":"Higuchi K, Shiba M, Okazaki H, et al. Four-year follow-up of the first case of gastroesophageal reflux disease treated with endoluminal gastroplication in Japan. J Gastroenterol. 2007;2:325\u20136.","journal-title":"J Gastroenterol"},{"key":"2022_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s00535-006-1944-5","volume":"42","author":"K Higuchi","year":"2007","unstructured":"Higuchi K, Fujiwara Y, Okazaki H, et al. Feasibility, safety, and efficacy of the Stretta procedure in Japanese patients with gastroesophageal reflux disease: first report from Asia. J Gastroenterol. 2007;42:205\u201310.","journal-title":"J Gastroenterol"},{"key":"2022_CR19","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.3109\/00365521.2014.978815","volume":"49","author":"K Ota","year":"2014","unstructured":"Ota K, Takeuchi T, Harada S, et al. A novel endoscopic submucosal dissection technique for proton pump inhibitor-refractory gastroesophageal reflux disease. Scand J Gastroenterol. 2014;49:1409\u201313.","journal-title":"Scand J Gastroenterol"},{"key":"2022_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/den.13727","author":"K Sumi","year":"2021","unstructured":"Sumi K, Inoue H, Kobayashi Y, et al. Endoscopic treatment of proton pump inhibitor-refractory gastroesophageal reflux disease with anti-reflux mucosectomy: Experience of 109 cases. Dig Endosc. 2021. https:\/\/doi.org\/10.1111\/den.13727.","journal-title":"Dig Endosc"},{"key":"2022_CR21","doi-asserted-by":"publisher","first-page":"E133","DOI":"10.1055\/a-1031-9436","volume":"8","author":"H Inoue","year":"2020","unstructured":"Inoue H, Tanabe M, de Santiago ER, et al. Anti-reflux mucosal ablation (ARMA) as a new treatment for gastroesophageal reflux refractory to proton pump inhibitors: a pilot study. Endosc Int Open. 2020;8:E133\u20138.","journal-title":"Endosc Int Open"},{"key":"2022_CR22","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.dld.2012.03.019","volume":"44","author":"PA Testoni","year":"2012","unstructured":"Testoni PA, Vailati C. Transoral incisionless fundoplication with EsophyX\u00ae for treatment of gastro-oesphageal reflux disease. Dig Liver Dis. 2012;44:631\u20135.","journal-title":"Dig Liver Dis"},{"key":"2022_CR23","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1052-5157(02)00115-0","volume":"13","author":"H Louis","year":"2003","unstructured":"Louis H, Devi\u00e8re J. Endoscopic implantation of enteryx for the treatment of gastroesophageal reflux disease: technique, pre-clinical and clinical experience. Gastrointest Endosc Clin N Am. 2003;13:191\u2013200.","journal-title":"Gastrointest Endosc Clin N Am"},{"key":"2022_CR24","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S1052-5157(02)00112-5","volume":"13","author":"P Fockens","year":"2003","unstructured":"Fockens P. Gatekeeper reflux repair system: technique, pre-clinical, and clinical experience. Gastrointest Endosc Clin N Am. 2003;13:179\u201389.","journal-title":"Gastrointest Endosc Clin N Am"},{"key":"2022_CR25","unstructured":"The Japanese Society of Gastroenterology. Evidence-based Clinical Practice Guidelines for Gastroesophageal Reflux Disease (GERD) 2021 (3rd Edition). Nankodo. 2021"},{"key":"2022_CR26","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/j.1442-2050.2009.00954.x","volume":"22","author":"H Mizuta","year":"2009","unstructured":"Mizuta H, Nishimori I, Kuratani Y, et al. Predictive factors for esophageal stenosis after endoscopic submucosal dissection for superficial esophageal cancer. Dis Esophagus. 2009;22:626\u201331.","journal-title":"Dis Esophagus"},{"key":"2022_CR27","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1007\/s00535-004-1417-7","volume":"39","author":"M Kusano","year":"2004","unstructured":"Kusano M, Shimoyama Y, Sugimoto S, et al. Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J Gastroenterol. 2004;39:888\u201391.","journal-title":"J Gastroenterol"},{"key":"2022_CR28","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/apt.15641","volume":"51","author":"T Takeuchi","year":"2020","unstructured":"Takeuchi T, Furuta T, Fujiwara Y, et al. Randomised trial of acid inhibition by vonoprazan 10\/20 mg once daily vs rabeprazole 10\/20 mg twice daily in healthy Japanese volunteers (SAMURAI pH study). Aliment Pharmacol Ther. 2020;51:534\u201343.","journal-title":"Aliment Pharmacol Ther"},{"key":"2022_CR29","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/bjs.1800770528","volume":"77","author":"GH Ferguson","year":"1990","unstructured":"Ferguson GH, MacLennan I, Taylor TV, et al. Outcome of revisional gastric surgery using a Roux-en-Y biliary diversion. Br J Surg. 1990;77:551\u20134.","journal-title":"Br J Surg"},{"key":"2022_CR30","first-page":"29","volume":"111","author":"DC Gotley","year":"1992","unstructured":"Gotley DC, Ball DE, Owen RW, et al. Evaluation and surgical correction of esophagitis after partial gastrectomy. Surgery. 1992;111:29\u201336.","journal-title":"Surgery"},{"key":"2022_CR31","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/nmo.12305","volume":"26","author":"A Pauwels","year":"2014","unstructured":"Pauwels A, Altan E, Tack J. The gastric accommodation response to meal intake determines the occurrence of transient lower esophageal sphincter relaxations and reflux events in patients with gastro-esophageal reflux disease. Neurogastroenterol Motil. 2014;26:581\u20138.","journal-title":"Neurogastroenterol Motil"},{"key":"2022_CR32","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1136\/gut.2003.033290","volume":"53","author":"D Sifrim","year":"2004","unstructured":"Sifrim D, Castell D, Dent J, Kahrilas PJ. Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut. 2004;53:1024\u201331.","journal-title":"Gut"},{"key":"2022_CR33","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/ajg.2014.63","volume":"109","author":"A Patel","year":"2014","unstructured":"Patel A, Sayuk GS, Gyawali CP. Acid-based parameters on pH-impedance testing predict symptom improvement with medical management better than impedance parameters. Am J Gastroenterol. 2014;109:836\u201344.","journal-title":"Am J Gastroenterol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-02022-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-021-02022-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-02022-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T21:04:16Z","timestamp":1699823056000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-021-02022-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,18]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2022"],"URL":"https:\/\/doi.org\/10.1186\/s12876-021-02022-x","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,18]]},"assertion":[{"value":"29 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study was a single-center, single-arm trial conducted at the Osaka Medical and Pharmaceutical University Hospital. The study was conducted in accordance with the 1975 Declaration of Helsinki (as revised in 1983). The protocol was approved by the ethics review committee at Osaka Medical and Pharmaceutical University (No. 0563, May 12, 2008 and No. 1507, March 3, 2016) and registered in the University Hospital Medical Information Network Clinical Trial Registry (UMIN000042538). We informed consent was obtained from all the participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflict of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"432"}}